EVERSANA and OptimizeRx Corp. announced their partnership to modernize the patient experience and improve health outcomes by combining a real-time electronic health records (EHR) network with customized, wraparound patient support services.
Prices, profits and promotional spend are closely linked. Reduce prices and promotion will plummet. But wait, the Republicans are in control. Accordingly, pharma, its marketing partners and even Wall Street often rest easy, especially when Republicans control Congress and the White House.
Novartis AG’s Sandoz division struck a deal with Taiwan’s EirGenix Inc. to market a biosimilar version of Roche’s Herceptin that is in late-stage development to treat some cancer tumors.
The U.S. FDA approved AbbVie Inc.’s Skyrizi as a treatment for plaque psoriasis at a time when the company’s blockbuster psoriasis medicine Humira faces patent pressures.
U.S. Food and Drug Administration Acting Commissioner Ned Sharpless said he plans to “maintain FDA’s current course of action in every area and proceed full-speed ahead,” according to a statement issued by the regulatory agency.
Although biosimilars have not had the immediate uptake in the United States that they have had in Europe, health plans expect these products will become a staple of therapy for some diseases by 2020 – if the price is right.
EVERSANA, the leading independent provider of global services to the life science industry, introduced a new suite of global market access solutions from Health Strategies Insights to help biopharmaceutical manufacturers understand the latest global trends in access, payment, distribution and administration.
Novartis’ generics chief stepped down after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale.
AbbVie’s Humira, the world’s top-selling prescription medicine since 2012, brought the Illinois-based company nearly $20 billion in revenue in 2018.
The U.S. Food and Drug Administration approved Pfizer Inc.’s biosimilar to Roche AG’s blockbuster breast cancer treatment Herceptin.
Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China
Samsung Bioepis Co. Ltd. announced the company’s expansion in mainland China through a licensing agreement with C-Bridge Capital. The transaction covers multiple biosimilar candidates from Samsung Bioepis, including third-wave biosimilar candidates SB11 and SB12 – which reference Lucentis (ranibizumab) and Soliris (eculizumab) – as well as the biosimilar candidate SB3 that references Herceptin (trastuzumab).